Invest Different
Results 1 - 10 of 545 : 1 2 3 4 5 6 7 8 9 Next
When Passing Your Clinical Trial Isn't Enough
Side effects ruin Amgen's day in front of the advisory committee.
This Just In: More Upgrades and Downgrades
New ratings for Amgen, Cisco, and Apollo Investment.
Is Avanir Pharmaceuticals the Perfect Stock?
Finding companies that have all the right stuff can produce winners.
Can Amgen Convince Docs to Recommend Approval?
It's going to be an uphill battle.
What's Going on With These Biotech Stocks?
Here's the news at three of the most interesting biotechs.
This Just In: Upgrades and Downgrades
Bank of America relents on Dendreon.
Whoa! What Just Happened to My Stock?
These stocks just took off, but are they about to make a return trip to Earth?
New CEO = Dendreon Takeover Target?
After Provenge launch, Dendreon looks for new leadership at Savient.
Side Effect of Low Side Effects: 20% Stock Gain
Medivation and Astellas have good news for patients and investors.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK